{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:15:05Z","timestamp":1787066105140,"version":"build-2736575974"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T00:00:00Z","timestamp":1690329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T00:00:00Z","timestamp":1690329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The objective of this study is to investigate potential biomarkers of Crohn's disease (CD) and the pathological importance of infiltration of associated immune cells in disease development using machine learning.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Three publicly accessible CD gene expression profiles were obtained from the GEO database. Inflammatory tissue samples were selected and differentiated between colonic and ileal tissues. To determine the differentially expressed genes (DEGs) between CD and healthy controls, the larger sample size was merged as a training unit. The function of DEGs was comprehended through disease enrichment (DO) and gene set enrichment analysis (GSEA) on DEGs. Promising biomarkers were identified using the support vector machine-recursive feature elimination and lasso regression models. To further clarify the efficacy of potential biomarkers as diagnostic genes, the area under the ROC curve was observed in the validation group. Additionally, using the CIBERSORT approach, immune cell fractions from CD patients were examined and linked with potential biomarkers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Thirty-four DEGs were identified in colon tissue, of which 26 were up-regulated and 8 were down-regulated. In ileal tissues, 50 up-regulated and 50 down-regulated DEGs were observed. Disease enrichment of colon and ileal DEGs primarily focused on immunity, inflammatory bowel disease, and related pathways. CXCL1, S100A8, REG3A, and DEFA6 in colon tissue and LCN2 and NAT8 in ileum tissue demonstrated excellent diagnostic value and could be employed as CD gene biomarkers using machine learning methods in conjunction with external dataset validation. In comparison to controls,\n                      <jats:italic>antigen processing and presentation, chemokine signaling pathway, cytokine\u2013cytokine receptor interactions, and natural killer cell-mediated cytotoxicity<\/jats:italic>\n                      were activated in colonic tissues.\n                      <jats:italic>Cytokine\u2013cytokine receptor interactions, NOD-like receptor signaling pathways, and toll-like receptor signaling pathways<\/jats:italic>\n                      were activated in ileal tissues. NAT8 was found to be associated with CD8 T cells, while CXCL1, S100A8, REG3A, LCN2, and DEFA6 were associated with neutrophils, indicating that immune cell infiltration in CD is closely connected.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>CXCL1, S100A8, REG3A, and DEFA6 in colonic tissue and LCN2 and NAT8 in ileal tissue can be employed as CD biomarkers. Additionally, immune cell infiltration is crucial for CD development.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40001-023-01200-9","type":"journal-article","created":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T00:02:21Z","timestamp":1690329741000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Predicting diagnostic biomarkers associated with immune infiltration in Crohn's disease based on machine learning and bioinformatics"],"prefix":"10.1186","volume":"28","author":[{"given":"Wenhui","family":"Bao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxiao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,26]]},"reference":[{"issue":"13","key":"1200_CR1","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.1016\/j.cgh.2019.04.040","volume":"17","author":"PS Dulai","year":"2019","unstructured":"Dulai PS, Singh S, Vande Casteele N, Boland BS, Rivera-Nieves J, Ernst PB, et al. Should we divide Crohn\u2019s disease into ileum-dominant and isolated colonic diseases? Clin Gastroenterol Hepatol. 2019;17(13):2634\u201343.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"1200_CR2","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41572-020-0156-2","volume":"6","author":"G Roda","year":"2020","unstructured":"Roda G, Chien Ng S, Kotze PG, Argollo M, Panaccione R, Spinelli A, et al. Crohn\u2019s disease. Nat Rev Dis Primers. 2020;6(1):22.","journal-title":"Nat Rev Dis Primers"},{"issue":"7","key":"1200_CR3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s11894-019-0698-1","volume":"21","author":"A Garber","year":"2019","unstructured":"Garber A, Regueiro M. Extraintestinal manifestations of inflammatory bowel disease: epidemiology, etiopathogenesis, and management. Curr Gastroenterol Rep. 2019;21(7):31.","journal-title":"Curr Gastroenterol Rep"},{"issue":"4","key":"1200_CR4","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1136\/gutjnl-2012-303661","volume":"62","author":"SC Ng","year":"2013","unstructured":"Ng SC, Bernstein CN, Vatn MH, Lakatos PL, Loftus EV Jr, Tysk C, et al. Geographical variability and environmental risk factors in inflammatory bowel disease. Gut. 2013;62(4):630\u201349.","journal-title":"Gut"},{"key":"1200_CR5","doi-asserted-by":"crossref","unstructured":"Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142(1):46\u201354.e42; quiz e30.","DOI":"10.1053\/j.gastro.2011.10.001"},{"issue":"7","key":"1200_CR6","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.mayocp.2017.04.010","volume":"92","author":"JD Feuerstein","year":"2017","unstructured":"Feuerstein JD, Cheifetz AS. Crohn disease: epidemiology, diagnosis, and management. Mayo Clin Proc. 2017;92(7):1088\u2013103.","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"1200_CR7","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/nrgastro.2017.136","volume":"15","author":"AN Ananthakrishnan","year":"2018","unstructured":"Ananthakrishnan AN, Bernstein CN, Iliopoulos D, Macpherson A, Neurath MF, Ali RAR, et al. Environmental triggers in IBD: a review of progress and evidence. Nat Rev Gastroenterol Hepatol. 2018;15(1):39\u201349.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"48","key":"1200_CR8","doi-asserted-by":"publisher","first-page":"5246","DOI":"10.3748\/wjg.v17.i48.5246","volume":"17","author":"EV Tsianos","year":"2011","unstructured":"Tsianos EV, Katsanos KH, Tsianos VE. Role of genetics in the diagnosis and prognosis of Crohn\u2019s disease. World J Gastroenterol. 2011;17(48):5246\u201359.","journal-title":"World J Gastroenterol"},{"issue":"11","key":"1200_CR9","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.2174\/1389450115666140908125738","volume":"15","author":"S Danese","year":"2014","unstructured":"Danese S, Fiorino G, Fernandes C, Peyrin-Biroulet L. Catching the therapeutic window of opportunity in early Crohn\u2019s disease. Curr Drug Targets. 2014;15(11):1056\u201363.","journal-title":"Curr Drug Targets"},{"issue":"2","key":"1200_CR10","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.disamonth.2017.07.001","volume":"64","author":"M Gajendran","year":"2018","unstructured":"Gajendran M, Loganathan P, Catinella AP, Hashash JG. A comprehensive review and update on Crohn\u2019s disease. Disease-a-month\u202f: DM. 2018;64(2):20\u201357.","journal-title":"Disease-a-month : DM"},{"issue":"10080","key":"1200_CR11","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1016\/S0140-6736(16)31711-1","volume":"389","author":"J Torres","year":"2017","unstructured":"Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn\u2019s disease. Lancet (London, England). 2017;389(10080):1741\u201355.","journal-title":"Lancet (London, England)"},{"issue":"7","key":"1200_CR12","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1097\/MIB.0b013e318281f54e","volume":"19","author":"JC Brazil","year":"2013","unstructured":"Brazil JC, Louis NA, Parkos CA. The role of polymorphonuclear leukocyte trafficking in the perpetuation of inflammation during inflammatory bowel disease. Inflamm Bowel Dis. 2013;19(7):1556\u201365.","journal-title":"Inflamm Bowel Dis"},{"issue":"9511","key":"1200_CR13","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/S0140-6736(06)68265-2","volume":"367","author":"DJ Marks","year":"2006","unstructured":"Marks DJ, Harbord MW, MacAllister R, Rahman FZ, Young J, Al-Lazikani B, et al. Defective acute inflammation in Crohn\u2019s disease: a clinical investigation. Lancet (London, England). 2006;367(9511):668\u201378.","journal-title":"Lancet (London, England)"},{"key":"1200_CR14","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.jbior.2016.11.001","volume":"63","author":"MP Espaillat","year":"2017","unstructured":"Espaillat MP, Kew RR, Obeid LM. Sphingolipids in neutrophil function and inflammatory responses: mechanisms and implications for intestinal immunity and inflammation in ulcerative colitis. Adv Biol Regul. 2017;63:140\u201355.","journal-title":"Adv Biol Regul"},{"issue":"1","key":"1200_CR15","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.mayocp.2018.09.013","volume":"94","author":"GP Ramos","year":"2019","unstructured":"Ramos GP, Papadakis KA. Mechanisms of disease: inflammatory bowel diseases. Mayo Clin Proc. 2019;94(1):155\u201365.","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"1200_CR16","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.immuni.2006.06.002","volume":"24","author":"CT Weaver","year":"2006","unstructured":"Weaver CT, Harrington LE, Mangan PR, Gavrieli M, Murphy KM. Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity. 2006;24(6):677\u201388.","journal-title":"Immunity"},{"issue":"6","key":"1200_CR17","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/ni.1882","volume":"11","author":"W O'Connor Jr","year":"2010","unstructured":"O\u2019Connor W Jr, Zenewicz LA, Flavell RA. The dual nature of T(H)17 cells: shifting the focus to function. Nat Immunol. 2010;11(6):471\u20136.","journal-title":"Nat Immunol"},{"issue":"8","key":"1200_CR18","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1097\/MIB.0b013e318281f5a3","volume":"19","author":"CG Mayne","year":"2013","unstructured":"Mayne CG, Williams CB. Induced and natural regulatory T cells in the development of inflammatory bowel disease. Inflamm Bowel Dis. 2013;19(8):1772\u201388.","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"1200_CR19","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.4049\/jimmunol.157.3.1261","volume":"157","author":"IJ Fuss","year":"1996","unstructured":"Fuss IJ, Neurath M, Boirivant M, Klein JS, de la Motte C, Strong SA, et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn\u2019s disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol. 1996;157(3):1261\u201370.","journal-title":"J Immunol"},{"key":"1200_CR20","doi-asserted-by":"crossref","unstructured":"Takayama T, Kamada N, Chinen H, Okamoto S, Kitazume MT, Chang J, et al. Imbalance of NKp44(+)NKp46(-) and NKp44(-)NKp46(+) natural killer cells in the intestinal mucosa of patients with Crohn's disease. Gastroenterology. 2010;139(3):882\u201392.e1\u20133.","DOI":"10.1053\/j.gastro.2010.05.040"},{"issue":"7","key":"1200_CR21","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1136\/gutjnl-2016-311785","volume":"65","author":"J Torres","year":"2016","unstructured":"Torres J, Burisch J, Riddle M, Dubinsky M, Colombel JF. Preclinical disease and preventive strategies in IBD: perspectives, challenges and opportunities. Gut. 2016;65(7):1061\u20139.","journal-title":"Gut"},{"issue":"3","key":"1200_CR22","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1136\/gutjnl-2012-302311","volume":"62","author":"ML H\u00f8ivik","year":"2013","unstructured":"H\u00f8ivik ML, Moum B, Solberg IC, Henriksen M, Cvancarova M, Bernklev T. Work disability in inflammatory bowel disease patients 10 years after disease onset: results from the IBSEN Study. Gut. 2013;62(3):368\u201375.","journal-title":"Gut"},{"issue":"2","key":"1200_CR23","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1053\/j.gastro.2007.05.051","volume":"133","author":"KF Fr\u00f8slie","year":"2007","unstructured":"Fr\u00f8slie KF, Jahnsen J, Moum BA, Vatn MH. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology. 2007;133(2):412\u201322.","journal-title":"Gastroenterology"},{"issue":"11","key":"1200_CR24","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1038\/ajg.2012.298","volume":"107","author":"L Peyrin-Biroulet","year":"2012","unstructured":"Peyrin-Biroulet L, Harmsen WS, Tremaine WJ, Zinsmeister AR, Sandborn WJ, Loftus EV Jr. Surgery in a population-based cohort of Crohn\u2019s disease from Olmsted County, Minnesota (1970\u20132004). Am J Gastroenterol. 2012;107(11):1693\u2013701.","journal-title":"Am J Gastroenterol"},{"key":"1200_CR25","doi-asserted-by":"crossref","unstructured":"Louis E, Collard A, Oger AF, Degroote E, Aboul Nasr El Yafi FA, Belaiche J. Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut. 2001;49(6):777\u201382.","DOI":"10.1136\/gut.49.6.777"},{"issue":"6","key":"1200_CR26","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1111\/apt.16536","volume":"54","author":"N Pierre","year":"2021","unstructured":"Pierre N, Sal\u00e9e C, Vieujean S, Bequet E, Merli AM, Siegmund B, et al. Review article: distinctions between ileal and colonic Crohn\u2019s disease: from physiology to pathology. Aliment Pharmacol Ther. 2021;54(6):779\u201391.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"1200_CR27","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3748\/wjg.v20.i1.31","volume":"20","author":"HJ Freeman","year":"2014","unstructured":"Freeman HJ. Natural history and long-term clinical course of Crohn\u2019s disease. World J Gastroenterol. 2014;20(1):31\u20136.","journal-title":"World J Gastroenterol"},{"issue":"2","key":"1200_CR28","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.crohns.2007.08.004","volume":"1","author":"S Odes","year":"2007","unstructured":"Odes S, Vardi H, Friger M, Wolters F, Hoie O, Moum B, et al. Effect of phenotype on health care costs in Crohn\u2019s disease: a European study using the Montreal classification. J Crohns Colitis. 2007;1(2):87\u201396.","journal-title":"J Crohns Colitis"},{"issue":"11","key":"1200_CR29","first-page":"661","volume":"98","author":"B Veauthier","year":"2018","unstructured":"Veauthier B, Hornecker JR. Crohn\u2019s disease: diagnosis and management. Am Fam Physician. 2018;98(11):661\u20139.","journal-title":"Am Fam Physician"},{"issue":"9","key":"1200_CR30","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/ajg.2015.233","volume":"110","author":"L Peyrin-Biroulet","year":"2015","unstructured":"Peyrin-Biroulet L, Sandborn W, Sands BE, Reinisch W, Bemelman W, Bryant RV, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015;110(9):1324\u201338.","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"1200_CR31","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1007\/s11894-014-0416-y","volume":"16","author":"T Billiet","year":"2014","unstructured":"Billiet T, Ferrante M, Van Assche G. The use of prognostic factors in inflammatory bowel diseases. Curr Gastroenterol Rep. 2014;16(11):416.","journal-title":"Curr Gastroenterol Rep"},{"issue":"11","key":"1200_CR32","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1177\/1756283X17732720","volume":"10","author":"PB Allen","year":"2017","unstructured":"Allen PB, Gower-Rousseau C, Danese S, Peyrin-Biroulet L. Preventing disability in inflammatory bowel disease. Ther Adv Gastroenterol. 2017;10(11):865\u201376.","journal-title":"Ther Adv Gastroenterol"},{"key":"1200_CR33","doi-asserted-by":"publisher","DOI":"10.1172\/JCI141676","author":"H Grasberger","year":"2021","unstructured":"Grasberger H, Magis AT, Sheng E, Conomos MP, Zhang M, Garzotto LS, et al. DUOX2 variants associate with preclinical disturbances in microbiota-immune homeostasis and increased inflammatory bowel disease risk. J Clin Invest. 2021. https:\/\/doi.org\/10.1172\/JCI141676.","journal-title":"J Clin Invest"},{"key":"1200_CR34","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.3389\/fimmu.2018.01298","volume":"9","author":"S Wang","year":"2018","unstructured":"Wang S, Song R, Wang Z, Jing Z, Wang S, Ma J. S100A8\/A9 in Inflammation. Front Immunol. 2018;9:1298.","journal-title":"Front Immunol"},{"issue":"Suppl 2","key":"1200_CR35","doi-asserted-by":"publisher","DOI":"10.1111\/eci.12983","volume":"48","author":"AW Segal","year":"2018","unstructured":"Segal AW. The role of neutrophils in the pathogenesis of Crohn\u2019s disease. Eur J Clin Invest. 2018;48(Suppl 2): e12983.","journal-title":"Eur J Clin Invest"},{"issue":"9","key":"1200_CR36","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1084\/jem.20091233","volume":"206","author":"AM Smith","year":"2009","unstructured":"Smith AM, Rahman FZ, Hayee B, Graham SJ, Marks DJ, Sewell GW, et al. Disordered macrophage cytokine secretion underlies impaired acute inflammation and bacterial clearance in Crohn\u2019s disease. J Exp Med. 2009;206(9):1883\u201397.","journal-title":"J Exp Med"},{"issue":"Pt 19","key":"1200_CR37","doi-asserted-by":"publisher","first-page":"3522","DOI":"10.1242\/jcs.050690","volume":"122","author":"S Lipinski","year":"2009","unstructured":"Lipinski S, Till A, Sina C, Arlt A, Grasberger H, Schreiber S, et al. DUOX2-derived reactive oxygen species are effectors of NOD2-mediated antibacterial responses. J Cell Sci. 2009;122(Pt 19):3522\u201330.","journal-title":"J Cell Sci"},{"issue":"4","key":"1200_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2012-13-4-r32","volume":"13","author":"S Schwartz","year":"2012","unstructured":"Schwartz S, Friedberg I, Ivanov IV, Davidson LA, Goldsby JS, Dahl DB, et al. A metagenomic study of diet-dependent interaction between gut microbiota and host in infants reveals differences in immune response. Genome Biol. 2012;13(4): r32.","journal-title":"Genome Biol"},{"issue":"3","key":"1200_CR39","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1093\/ajcn\/71.3.807","volume":"71","author":"E Levy","year":"2000","unstructured":"Levy E, Rizwan Y, Thibault L, Lepage G, Brunet S, Bouthillier L, et al. Altered lipid profile, lipoprotein composition, and oxidant and antioxidant status in pediatric Crohn disease. Am J Clin Nutr. 2000;71(3):807\u201315.","journal-title":"Am J Clin Nutr"},{"issue":"8","key":"1200_CR40","doi-asserted-by":"publisher","first-page":"3617","DOI":"10.1172\/JCI75436","volume":"124","author":"Y Haberman","year":"2014","unstructured":"Haberman Y, Tickle TL, Dexheimer PJ, Kim MO, Tang D, Karns R, et al. Pediatric Crohn disease patients exhibit specific ileal transcriptome and microbiome signature. J Clin Investig. 2014;124(8):3617\u201333.","journal-title":"J Clin Investig"},{"issue":"27","key":"1200_CR41","doi-asserted-by":"publisher","first-page":"18269","DOI":"10.1074\/jbc.C600095200","volume":"281","author":"H Grasberger","year":"2006","unstructured":"Grasberger H, Refetoff S. Identification of the maturation factor for dual oxidase. Evolution of an eukaryotic operon equivalent. J Biol Chem. 2006;281(27):18269\u201372.","journal-title":"J Biol Chem"},{"issue":"7","key":"1200_CR42","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.it.2010.05.003","volume":"31","author":"YS Bae","year":"2010","unstructured":"Bae YS, Choi MK, Lee WJ. Dual oxidase in mucosal immunity and host-microbe homeostasis. Trends Immunol. 2010;31(7):278\u201387.","journal-title":"Trends Immunol"},{"issue":"7758","key":"1200_CR43","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/s41586-019-1237-9","volume":"569","author":"J Lloyd-Price","year":"2019","unstructured":"Lloyd-Price J, Arze C, Ananthakrishnan AN, Schirmer M, Avila-Pacheco J, Poon TW, et al. Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. Nature. 2019;569(7758):655\u201362.","journal-title":"Nature"},{"issue":"7","key":"1200_CR44","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1097\/MIB.0000000000001066","volume":"23","author":"SN Hong","year":"2017","unstructured":"Hong SN, Joung JG, Bae JS, Lee CS, Koo JS, Park SJ, et al. RNA-seq reveals transcriptomic differences in inflamed and noninflamed intestinal mucosa of Crohn\u2019s disease patients compared with normal mucosa of healthy controls. Inflamm Bowel Dis. 2017;23(7):1098\u2013108.","journal-title":"Inflamm Bowel Dis"},{"issue":"4","key":"1200_CR45","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1093\/ecco-jcc\/jjz165","volume":"14","author":"E Eliadou","year":"2020","unstructured":"Eliadou E, Moleiro J, Ribaldone DG, Astegiano M, Rothfuss K, Taxonera C, et al. Interstitial and granulomatous lung disease in inflammatory bowel disease patients. J Crohns Colitis. 2020;14(4):480\u20139.","journal-title":"J Crohns Colitis"},{"issue":"1","key":"1200_CR46","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ajo.2012.01.016","volume":"154","author":"J Abbasian","year":"2012","unstructured":"Abbasian J, Martin TM, Patel S, Tessler HH, Goldstein DA. Immunologic and genetic markers in patients with idiopathic ocular inflammation and a family history of inflammatory bowel disease. Am J Ophthalmol. 2012;154(1):72\u20137.","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"1200_CR47","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1093\/ecco-jcc\/jjv178","volume":"10","author":"S Taleban","year":"2016","unstructured":"Taleban S, Li D, Targan SR, Ippoliti A, Brant SR, Cho JH, et al. Ocular manifestations in inflammatory bowel disease are associated with other extra-intestinal manifestations, gender, and genes implicated in other immune-related traits. J Crohns Colitis. 2016;10(1):43\u20139.","journal-title":"J Crohns Colitis"},{"issue":"8","key":"1200_CR48","volume":"13","author":"AH Sange","year":"2021","unstructured":"Sange AH, Srinivas N, Sarnaik MK, Modi S, Pisipati Y, Vaidya S, et al. Extra-intestinal manifestations of inflammatory bowel disease. Cureus. 2021;13(8): e17187.","journal-title":"Cureus"},{"issue":"6","key":"1200_CR49","first-page":"33","volume":"7","author":"DG Ribaldone","year":"2020","unstructured":"Ribaldone DG, Brigo S, Mangia M, Saracco GM, Astegiano M, Pellicano R. Oral manifestations of inflammatory bowel disease and the role of non-invasive surrogate markers of disease activity. Medicines (Basel, Switzerland). 2020;7(6):33.","journal-title":"Medicines (Basel, Switzerland)."},{"issue":"4","key":"1200_CR50","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1053\/j.gastro.2021.07.042","volume":"161","author":"G Rogler","year":"2021","unstructured":"Rogler G, Singh A, Kavanaugh A, Rubin DT. Extraintestinal manifestations of inflammatory bowel disease: current concepts, treatment, and implications for disease management. Gastroenterology. 2021;161(4):1118\u201332.","journal-title":"Gastroenterology"},{"issue":"5","key":"1200_CR51","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/nri3661","volume":"14","author":"MF Neurath","year":"2014","unstructured":"Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol. 2014;14(5):329\u201342.","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"1200_CR52","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.cgh.2006.11.014","volume":"5","author":"B Diosdado","year":"2007","unstructured":"Diosdado B, van Bakel H, Strengman E, Franke L, van Oort E, Mulder CJ, et al. Neutrophil recruitment and barrier impairment in celiac disease: a genomic study. Clin Gastroenterol Hepatol. 2007;5(5):574\u201381.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"1200_CR53","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1136\/gutjnl-2013-306518","volume":"64","author":"RF Leal","year":"2015","unstructured":"Leal RF, Planell N, Kajekar R, Lozano JJ, Ord\u00e1s I, Dotti I, et al. Identification of inflammatory mediators in patients with Crohn\u2019s disease unresponsive to anti-TNF\u03b1 therapy. Gut. 2015;64(2):233\u201342.","journal-title":"Gut"},{"key":"1200_CR54","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/296149","volume":"2015","author":"MR Tardif","year":"2015","unstructured":"Tardif MR, Chapeton-Montes JA, Posvandzic A, Pag\u00e9 N, Gilbert C, Tessier PA. Secretion of S100A8, S100A9, and S100A12 by neutrophils involves reactive oxygen species and potassium efflux. J Immunol Res. 2015;2015: 296149.","journal-title":"J Immunol Res"},{"issue":"8","key":"1200_CR55","doi-asserted-by":"publisher","first-page":"e72138","DOI":"10.1371\/journal.pone.0072138","volume":"8","author":"JC Simard","year":"2013","unstructured":"Simard JC, Cesaro A, Chapeton-Montes J, Tardif M, Antoine F, Girard D, et al. S100A8 and S100A9 induce cytokine expression and regulate the NLRP3 inflammasome via ROS-dependent activation of NF-\u03baB(1.). PLoS ONE. 2013;8(8):e72138.","journal-title":"PLoS ONE"},{"issue":"6","key":"1200_CR56","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1007\/s10620-010-1494-9","volume":"56","author":"AC Manolakis","year":"2011","unstructured":"Manolakis AC, Kapsoritakis AN, Tiaka EK, Potamianos SP. Calprotectin, calgranulin C, and other members of the s100 protein family in inflammatory bowel disease. Dig Dis Sci. 2011;56(6):1601\u201311.","journal-title":"Dig Dis Sci"},{"issue":"10","key":"1200_CR57","first-page":"2327","volume":"21","author":"J Stallhofer","year":"2015","unstructured":"Stallhofer J, Friedrich M, Konrad-Zerna A, Wetzke M, Lohse P, Glas J, et al. Lipocalin-2 Is a disease activity marker in inflammatory bowel disease regulated by IL-17A, IL-22, and TNF-\u03b1 and modulated by IL23R genotype status. Inflamm Bowel Dis. 2015;21(10):2327\u201340.","journal-title":"Inflamm Bowel Dis"},{"issue":"8","key":"1200_CR58","doi-asserted-by":"publisher","first-page":"565","DOI":"10.3109\/1354750X.2015.1123354","volume":"20","author":"V Abella","year":"2015","unstructured":"Abella V, Scotece M, Conde J, G\u00f3mez R, Lois A, Pino J, et al. The potential of lipocalin-2\/NGAL as biomarker for inflammatory and metabolic diseases. Biomarkers. 2015;20(8):565\u201371.","journal-title":"Biomarkers"},{"key":"1200_CR59","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1146\/annurev-nutr-071816-064559","volume":"37","author":"X Xiao","year":"2017","unstructured":"Xiao X, Yeoh BS, Vijay-Kumar M. Lipocalin 2: an emerging player in iron homeostasis and inflammation. Annu Rev Nutr. 2017;37:103\u201330.","journal-title":"Annu Rev Nutr"},{"issue":"3","key":"1200_CR60","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1053\/j.gastro.2006.05.051","volume":"131","author":"RJ Playford","year":"2006","unstructured":"Playford RJ, Belo A, Poulsom R, Fitzgerald AJ, Harris K, Pawluczyk I, et al. Effects of mouse and human lipocalin homologues 24p3\/lcn2 and neutrophil gelatinase-associated lipocalin on gastrointestinal mucosal integrity and repair. Gastroenterology. 2006;131(3):809\u201317.","journal-title":"Gastroenterology"},{"issue":"6093","key":"1200_CR61","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1126\/science.1218831","volume":"337","author":"H Chu","year":"2012","unstructured":"Chu H, Pazgier M, Jung G, Nuccio SP, Castillo PA, de Jong MF, et al. Human \u03b1-defensin 6 promotes mucosal innate immunity through self-assembled peptide nanonets. Science (New York, NY). 2012;337(6093):477\u201381.","journal-title":"Science (New York, NY)"},{"key":"1200_CR62","doi-asserted-by":"publisher","first-page":"646","DOI":"10.3389\/fimmu.2020.00646","volume":"11","author":"J Wehkamp","year":"2020","unstructured":"Wehkamp J, Stange EF. An update review on the Paneth cell as key to Ileal Crohn\u2019s disease. Front Immunol. 2020;11:646.","journal-title":"Front Immunol"},{"issue":"5","key":"1200_CR63","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1097\/MIB.0000000000000707","volume":"22","author":"R Hayashi","year":"2016","unstructured":"Hayashi R, Tsuchiya K, Fukushima K, Horita N, Hibiya S, Kitagaki K, et al. Reduced human \u03b1-defensin 6 in noninflamed Jejunal tissue of patients with Crohn\u2019s disease. Inflamm Bowel Dis. 2016;22(5):1119\u201328.","journal-title":"Inflamm Bowel Dis"},{"issue":"4","key":"1200_CR64","doi-asserted-by":"publisher","first-page":"3921","DOI":"10.18632\/oncotarget.6473","volume":"7","author":"Y Ye","year":"2016","unstructured":"Ye Y, Xiao L, Wang SJ, Yue W, Yin QS, Sun MY, et al. Up-regulation of REG3A in colorectal cancer cells confers proliferation and correlates with colorectal cancer risk. Oncotarget. 2016;7(4):3921\u201333.","journal-title":"Oncotarget"},{"issue":"8","key":"1200_CR65","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1111\/apt.12920","volume":"40","author":"I Marafini","year":"2014","unstructured":"Marafini I, Di Sabatino A, Zorzi F, Monteleone I, Sedda S, Cupi ML, et al. Serum regenerating islet-derived 3-alpha is a biomarker of mucosal enteropathies. Aliment Pharmacol Ther. 2014;40(8):974\u201381.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"1200_CR66","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0084957","volume":"9","author":"T Nunes","year":"2014","unstructured":"Nunes T, Etchevers MJ, Sandi MJ, Pin\u00f3 Donnay S, Grandjean T, Pellis\u00e9 M, et al. Pancreatitis-associated protein does not predict disease relapse in inflammatory bowel disease patients. PLoS ONE. 2014;9(1): e84957.","journal-title":"PLoS ONE"},{"issue":"1","key":"1200_CR67","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2215\/CJN.08600520","volume":"16","author":"S Luo","year":"2020","unstructured":"Luo S, Surapaneni A, Zheng Z, Rhee EP, Coresh J, Hung AM, et al. NAT8 variants, N-acetylated amino acids, and progression of CKD. CJASN. 2020;16(1):37\u201347.","journal-title":"CJASN"},{"issue":"3","key":"1200_CR68","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1111\/cas.15248","volume":"113","author":"H Jiang","year":"2022","unstructured":"Jiang H, Tang E, Chen Y, Liu H, Zhao Y, Lin M, et al. Squalene synthase predicts poor prognosis in stage I\u2013III colon adenocarcinoma and synergizes squalene epoxidase to promote tumor progression. Cancer Sci. 2022;113(3):971\u201385.","journal-title":"Cancer Sci"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-023-01200-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-023-01200-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-023-01200-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T01:04:02Z","timestamp":1690333442000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-023-01200-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,26]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1200"],"URL":"https:\/\/doi.org\/10.1186\/s40001-023-01200-9","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,26]]},"assertion":[{"value":"11 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"There is no conflict of interest, according to the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"255"}}